Niagen Bioscience Business Summary

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corporation, operates a vertically integrated biotechnology model focused on the discovery and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors. The company generates revenue through three core segments: Consumer Products, led by the Tru Niagen oral supplement brand; Ingredients, involving the B2B licensing of patented nicotinamide riboside (NR) to global partners; and the high-growth Niagen Plus division, which distributes pharmaceutical-grade IV and injectable products via a network of over 1,000 clinics and a proprietary telehealth platform. As of early 2026, the firm has maintained a 25-30% annual revenue growth trajectory by expanding its clinical footprint and at-home injection services. Niagen Bioscience competes directly with Elysium Health, Thorne HealthTech, USANA Health Sciences, and Nature’s Sunshine Products, distinguishing itself as the primary patent holder and scientific authority in the NR longevity market. The leadership team is headed by CEO Robert Fried, a veteran entrepreneur with a background in scaling media and wellness ventures, who has overseen the company’s transition into a high-margin consumer health entity since 2018. Co-founder Frank L. Jaksch Jr. continues to drive strategic research and pharmaceutical partnerships, while CFO Ozan Pamir manages the firm’s capital allocation, including a $10 million share repurchase program initiated in late 2025. The company’s scientific pedigree is anchored by Chief Scientific Advisor Dr. Charles Brenner, the world-renowned discoverer of NR’s role in cellular metabolism, and Dr. Andrew Shao, SVP of Global Regulatory and Scientific Affairs. This executive core is supported by a Scientific Advisory Board featuring Nobel laureates and elite researchers, reinforcing the company's reputation as the global leader in NAD+ science.